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Abstract
 
Glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) is a member
of the tumor necrosis factor receptor (TNFR) family that is expressed at low levels on unstim-
ulated T cells, B cells, and macrophages. Upon activation, CD4
 
 
 
 and CD8
 
 
 
 T cells up-regulate
GITR expression, whereas immunoregulatory T cells constitutively express high levels of GITR.
Here, we show that GITR may regulate alloreactive responses during graft-versus-host disease
(GVHD) after allogeneic bone marrow transplantation (BMT). Using a BMT model with major
histocompatibility complex class I and class II disparity, we demonstrate that GITR stimulation
in vitro and in vivo enhances alloreactive CD8
 
 
 
CD25
 
 
 
 T cell proliferation, whereas it decreases
alloreactive CD4
 
 
 
CD25
 
 
 
 proliferation. Allo-stimulated CD4
 
 
 
CD25
 
 
 
 cells show increased
apoptosis upon GITR stimulation that is dependent on the Fas–FasL pathway. Recipients of an
allograft containing CD8
 
 
 
CD25
 
 
 
 donor T cells had increased GVHD morbidity and mortality
in the presence of GITR-activating antibody (Ab). Conversely, recipients of an allograft with
CD4
 
 
 
CD25
 
 
 
 T cells showed a significant decrease in GVHD when treated with a GITR-
activating Ab. Our findings indicate that GITR has opposite effects on the regulation of allore-
active CD4
 
 
 
 and CD8
 
 
 
 T cells.
Key words: transplantation immunology • in vivo animal models • immune regulation • 
lymphocyte activation • T lymphocyte subsets
 
Introduction
 
Glucocorticoid-induced tumor necrosis factor receptor
family-related gene (GITR), also known as TNFRSF18, is
a type I transmembrane protein with high homology to
other members of the TNFR family, including 4-1BB,
CD27, and OX40 (1, 2). As with other members of the
TNFR family, signaling through GITR may induce cell
survival or cell death. Stimulation of human and mouse T
cells through GITR induces NF
 
 
 
B activation via the
TRAF2–NIK signaling pathway (3, 4). The intracellular
domain of GITR binds Siva, a cytoplasmic molecule that
contains a death domain, and may signal for induction of
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cell death (5). Four splice variants that differ in GITR in-
tracellular domain have been identified. These cytoplasmic
distinctions may generate different signaling events, and
one of them may encode a decoy receptor (6). Mouse mac-
rophages express constitutive levels of GITR–GITR ligand
(GITRL) and stimulation with soluble GITR (sGITR)
leads to an increased production of nitric oxide (7),
COX-2 (8), and MMP-9 (9). Macrophage stimulation with
sGITR signals through the Rel–NF
 
 
 
B pathway, but it re-
mains to be determined if sGITR is an agonist or antago-
nist of GITR signaling (10). In vitro studies using murine
GITRL protein and GITRL transfectants demonstrate that
GITR signaling can enhance or inhibit the proliferation of
Ag-stimulated T helper 1, T helper 2, and naive CD4
 
 
 
 T
cells from TCR transgenic mice depending on the concen-
tration of the cognate peptide, thus suggesting that GITR
can function as a costimulatory receptor for TCR activa-
tion (11). Mice deficient for GITR have normal lymphoid
and T cell development (12). However, experiments with
GITR
 
   
 
 T cells showed hyperproliferation to TCR stim-
ulation, increased IL-2 production, increased IL-2 receptor
 
 
 
 chain (CD25) expression, and increased susceptibility to
activation-induced cell death (AICD) (12). The human
GITRL has been detected in several tissues including
ovary, testis, kidney, pancreas, PBLs, lymph nodes, and hu-
man umbilical vein endothelial cells (3, 4). Mouse GITRL
expression has been demonstrated in macrophages, B cells,
and both immature and mature dendritic cells (11, 13, 14).
Stimulation with mitogens or LPS results in a temporary
increase in the expression levels of GITRL, which is regu-
lated by the transcription factor NF-1(11).
Mouse models for autoimmune disease suggest that
GITR activation may break self-tolerance and induce au-
toimmunity presumably by inhibition of immunoregula-
tory T cell suppression (15, 16). In vivo administration
of the agonist anti-GITR Ab, DTA-1, does not deplete
GITR-expressing cells (15), but the mechanism by which
immunoregulatory T cells are inhibited by GITR activa-
tion or the effect of GITR stimulation on other cell types
such as B cells has not been defined. Apart from in vitro
studies suggesting a costimulatory role for GITR in CD4
 
 
 
T cell activation (11, 15, 17, 18), the function of GITR on
CD4
 
 
 
CD25
 
 
 
 and especially CD8
 
 
 
CD25
 
 
 
 remains largely
unknown. Because GITR expression is up-regulated upon
stimulation of T cells, we were interested in studying
GITR expression and activation of alloreactive CD4
 
 
 
CD25
 
 
 
 and CD8
 
 
 
CD25
 
 
 
 T cells and its effects on the de-
velopment of GVHD.
 
Materials and Methods
 
Reagents and Antibodies. 
 
The DTA-1 hybridoma was gener-
ated as described previously (15), and rat IgG control Ab was
obtained from Anogen. Antimurine CD16/CD32 FcR block
(2.4G2), TNFR1 (55R-593), TNF (MP6-XT3), and all of the
following fluorochrome labeled and purified antibodies against
murine Ag were obtained from BD Biosciences: CD4 (RM4-5),
CD8 (53-6.7), CD62L (MEL-14), CD122 (TM-B1), CD44
(IM7), CD45R/B220 (RA3-6B2), Gr-1 (RB6-8C5), CD25
(PC61), CD69 (H1.2F3), H-2Kb (AF6-88.5), Ly 9.1 (30C7), Fas
(JO2), FasL (MFL3), isotype controls; rat IgG2a-
 
 
 
 (R35-95), rat
IgG2a-
 
 
 
 (B39-4), rat IgG2b (A95-1), hamster IgG group 1 liter
(Ha4/8), streptavidin-FITC, -PE, and -PCP. Biotinylated anti-
murine GITR (BAF524) was obtained from R&D Systems. Car-
boxyfluorescein succinimidyl ester (CFSE) was obtained from
Molecular Probes.
 
In Vitro Assays. 
 
Tissue culture medium consisted of RPMI
1640 or DMEM supplemented with 10% heat inactivated FBS,
100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin, 2 mM 
 
l
 
-glutamine,
and 50 
 
 
 
M of 2-mercaptoethanol (2-ME). For Ab stimulation, 1
 
 
 
g/ml anti-CD3 and anti-CD28 was used. For proliferation assays,
10 
 
 
 
g/ml DTA-1 or rat IgG control Ab was used. T cells were pu-
rified, and 10
 
5
 
 cells/well were incubated for 6 d with irradiated
(2,000 cGy) splenocytes as stimulators (2 
 
 
 
 10
 
5
 
 cells/well) in 96-
well plates. Cultures were pulsed during the final 18 h with 1 
 
 
 
Ci/
well thymidine and harvested with Topcount Harvester (19). Cell
proliferation was determined as counts per minute.
 
BMT and T Cell Purification. 
 
Female C57BL/6 (H-2
 
b
 
),
BALB/c (H-2
 
k
 
), B10.BR (H-2
 
k
 
), CBA/J(H-2
 
k
 
), 
 
lpr
 
 (B6.MRL-
 
Fas
 
lpr
 
), and C57BL/6 (Ly5.1
 
 
 
) were obtained from The Jackson
Laboratory. GITR
 
   
 
 mice (C57BL/6 
 
 
 
 129/SvJ) were gener-
ated at Memorial Sloan-Kettering (12). All mice were used be-
tween 8–10 wk of age. BM cells were removed aseptically from
femurs and tibias and depleted of T cells by incubation with anti–
Thy-1.2 for 30 min at 4
 
 
 
C followed by incubation with Low-
TOX-M rabbit complement (Cedarlane Laboratories) for 40 min
at 37
 
 
 
C. Cells (5 
 
 
 
 10
 
6
 
 BM cells without splenic T cells) were
resuspended in DMEM (Life Technologies) and transplanted by
tail vein infusion (0.25 ml total volume) into lethally irradiated
recipients on day 0. On day 0, before transplantation, recipients
received 900 cGy (BALB/c) or 1300 cGy (CBA/J) total body ir-
radiation (
 
137
 
Cs source) as a split dose with a 3-h interval between
doses (to reduce gastrointestinal toxicity). T cells were obtained
from spleens, purified over a nylon wool column, or positively
selected with anti-CD5 magnetic beads. CD4
 
 
 
CD25
 
 
 
 and
CD8
 
 
 
CD25
 
 
 
 T cells were purified with magnetic beads (
 
 
 
90%
purity; Miltenyi Biotec) or sorted with Moflow (
 
 
 
98–99%
purity; DakoCytomation). Experiments were performed with
sorted fractions and confirmed with bead-purified T cells. In
brief, CD25
 
 
 
 T cells were obtained by negative selection of sple-
nocytes treated with anti-CD25 PE-conjugated Ab and anti-PE
microbeads. CD4
 
 
 
 and CD8
 
 
 
 fractions were separated by posi-
tive selection for anti-CD4 or anti-CD8 antibodies conjugated to
microbeads. Mice were housed in sterilized micro-isolator cages
and received normal chow and autoclaved hyperchlorinated
drinking water (pH 3.0). All experiments were performed in ac-
cordance with our institutional guidelines.
 
Assessment of GVHD. 
 
The severity of GVHD was assessed
with a clinical GVHD scoring system as described previously
(20). In brief, mice were individually scored every week for five
clinical parameters on a scale from zero to two: weight loss, pos-
ture, activity, fur, and skin. A clinical GVHD index was gener-
ated by summation of the five criteria scores (0–10). Survival was
monitored daily. Animals with scores 
 
 
 
5 were considered mori-
bund and were killed. GVHD organ pathology for bowel (termi-
nal ileum and ascending colon) and liver was assessed in a blinded
fashion on formalin-preserved, paraffin-embedded, hematoxylin
and eosin–stained histopathology sections with a semi-quantita-
tive scoring system. In brief, bowel and liver were scored for 18–
22 parameters associated with GVHD as described previously
(21, 22). 
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CFSE Labeling. 
 
Cells were labeled with CFSE as described
previously (23). In brief, T cells were incubated with CFSE at a
final concentration of 2.5 
 
 
 
M in PBS at 37
 
 
 
C for 20 min. Cells
were washed three times with PBS before i.v. injection.
 
Flow Cytometric Analysis. 
 
T cells were washed in FACS
 
®
 
buffer (PBS with 2% FBS and 0.1% sodium azide) and incubated
for 15 min at 4
 
 
 
C with anti-CD16/CD32 FcR block. Subse-
quently, cells were incubated for 30 min at 4
 
 
 
C with antibodies
and washed twice with FACS
 
®
 
 buffer. Stained cells were resus-
pended in FACS
 
®
 
 buffer and analyzed on a FACSCalibur™ flow
cytometer (Becton Dickinson) with CELLQuest™ or Flowjo
software (Treestar). For annexin V analysis, after cell surface
staining, the stained cells were resuspended in 100 
 
 
 
l annexin V
binding buffer and 5 
 
 
 
l annexin V Ab. After a 20-min incubation
at room temperature in the dark, an additional 300 
 
 
 
l annexin V
binding buffer was added, and the cells were analyzed.
 
ELISA. 
 
MLR supernatant IL-2 and IFN
 
 
 
 levels were per-
formed according to the manufacturer’s instructions with Quan-
tikine M kits from R&D Systems.
 
DTA-1 Administration. 
 
For GVHD studies, DTA-1 and rat
isotype control was administered by i.p. at days 
 
 
 
1, 6, and 13 (1
mg/day). For adoptive transfer experiments with CFSE-labeled T
cells, the antibodies were administered at day 
 
 
 
1 (1 mg i.p.).
 
Online Supplemental Material.
 
The opposite effects of GITR
stimulation on CD4
 
 
 
CD25
 
 
 
 and CD8
 
 
 
CD25
 
 
 
 T cells remain
even at different concentrations of DTA-1 Ab and are inde-
pendent from the TNF–TNFR pathway. Supernatants from
CD4
 
 
 
CD25
 
 
 
 T cells activated in the presence of GITR stimula-
tion have decreased levels of IL-2 and IFN
 
 
 
. Online supplemen-
tal material is available at http://www.jem.org/cgi/content/full/
jem.20040116/DC1.
 
Results
 
Alloreactive CD4
 
 
 
 and CD8
 
 
 
 T Cells Up-regulate GITR.
 
To assess whether activation of CD4
 
 
 
 and CD8
 
 
 
 T cells
results in up-regulation of GITR expression, we analyzed
GITR cell surface expression on activated (in vitro stimula-
tion with anti-CD3 and anti-CD28 antibodies) and allo-
reactive (in vivo alloactivation after transfer into an allo-
geneic recipient) CD4
 
 
 
 and CD8
 
 
 
 T cells. In vitro
stimulation with plate-bound anti-CD3/anti-CD28 anti-
bodies of CD4 CD25  and CD8 CD25  T cells enhanced
the expression of cell surface GITR, whereas freshly iso-
lated immunoregulatory T cells had constitutive high levels
of GITR (unpublished data). We used an MHC class I/II
disparate model (C57BL/6→BALB/c) to analyze the ex-
pression of GITR on alloreactive T cells in vivo in two
ways. First, we infused CFSE-labeled donor CD3  T cells
into sublethally irradiated allogeneic and syngeneic recipi-
ents and recovered the cells from the spleen 3 d after infu-
sion (Fig. 1 A). CFSE-labeled donor T cells from syngeneic
recipients expressed low levels of cell surface GITR, in con-
trast with fast-dividing donor alloreactive T cells recovered
from allogeneic recipients that had an activated phenotype
(CD25  and CD44 ) and increased levels of GITR on
their surface. Second, we infused T cell–depleted (TCD)
allo-BM (C57BL/6 TCD-BM) and allogeneic T cells
(C57BL/6) into lethally irradiated recipients (BALB/c),
and after 9 d, determined the GITR expression on donor T
cells from the spleens of these recipients (Fig. 1 B). We
found that these (alloreactive) donor T cells indeed had an
activated phenotype (CD25 , CD44 , and CD62L ; un-
published data), and as expected, both CD4  and CD8 
donor T cells had increased GITR expression. Therefore,
we conclude that alloreactive CD4  and CD8  T cells up-
regulate their GITR expression.
Paradoxical Effect of GITR on CD4 CD25  and CD8 
CD25  T Cells. We studied the effects of GITR
stimulation on alloreactive T cells using an anti-GITR ago-
nist mAb (DTA-1) for in vitro and in vivo experiments. To
exclude the previously described effects of GITR on im-
munoregulatory T cells (15), we used purified C57BL/6
CD4 CD25  and CD8 CD25  T cells as effectors in
MLR experiments with MHC class I/II disparate irradiated
stimulators (BALB/c; Fig. 2 A). Addition of DTA-1 to the
MLR resulted in an  2-fold decrease in proliferation of
CD4 CD25  T cells, whereas CD8 CD25  T cell prolif-
eration increased by  3.5-fold when compared with addi-
tion of control Ab (Fig. 2 A, top). To eliminate potentially
confounding variables associated with GITR expression
on immunoregulatory T cells, B cells, and macrophages
present in the splenocyte population used as stimulators,
splenocytes isolated from GITR    and GITR    mice
were tested as stimulators. Because these mice are on a
Figure 1. Alloactivation induces up-regulation of cell surface GITR on
T cells. (A) Sublethally irradiated (750 cGy) syngeneic hosts (C57BL/6
Ly5.1) and allogeneic hosts (BALB/c) were infused with CFSE-labeled
donor T cells (C57BL/6). GITR, CD25, and CD44 expression of these
donor T cells was determined 3 d after infusion. (B) 9 d after BMT,
GITR and CD25 expression was determined on splenic T cells from
BALB/c recipients of C57BL/6 TCD-BM (5   106) and T cells (0.5   106),
which were developing GVHD (red histogram). Blue histograms repre-
sent untransplanted controls (light blue, C57BL/6; dark blue, BALB/c).Paradoxical Effect of GITR Activation on Alloreactive T Cells 152
mixed H2b background (C57BL/6   129/SvJ), we used
purified CD4 CD25  and CD8 CD25  T cells from
BALB/c mice as effectors (Fig. 2 A, bottom). Again, CD4 
CD25  T cells showed decreased proliferation, whereas
CD8 CD25  T cell proliferation was enhanced by the
addition of the DTA-1 Ab. Because this effect was
observed using GITR    stimulators, we conclude that
GITR stimulation via DTA-1 is independent of GITR ex-
pression on the stimulator population (including immuno-
regulatory T cells) and has a direct effect on CD4 CD25 
and CD8 CD25  effector T cells. Also, this effect was not
strain specific because results generated from T cells derived
from C57BL/6 and BALB/c were consistent.
Our experiments clearly show inhibition of CD4 
CD25  proliferation upon GITR stimulation, whereas
other groups show enhancement of CD4 CD25  T
cell  proliferation. Shimizu et al. (15) demonstrated that
CD4 CD25  T cells from CD28    were able to prolifer-
ate when stimulated via GITR. Tone et al. (11) showed
that stimulation of GITR using a recombinant mouse
GITRL could increase the proliferation of a Th2 clone
through a wide range of cognate peptide concentration and
a Th1 clone only at low peptide concentrations. Therefore,
we analyzed whether the difference in proliferation of the
alloreactive T cells could depend on the amount of anti-
GITR agonist Ab present in the MLR. Because the Ag
concentration is fixed (allorecognition), we titrated the
anti-GITR Ab concentration over a 4-log range (Fig.
S1, available at http://www.jem.org/cgi/content/full/jem.
20040116/DC1). Addition of different concentrations
spanning from 0.01 to 10  g/ml of the GITR-stimulating
Ab (DTA-1) to an MLR resulted again in decreased prolif-
eration of CD4 CD25  T cells and increased CD8 
CD25  T cell proliferation.
Our data would suggest that CD4 CD25  T cells from
GITR    mice would show increased proliferation,
whereas CD8 CD25  T cells from GITR    mice would
have impaired proliferative capacity. Ronchetti et al.
(17) have shown that, indeed, upon anti-CD3 stimulation,
CD4  but not the CD8  GITR    subpopulation had a
higher proliferation rate than the CD4  GITR    subpop-
ulation. Because T cell responses to Ab stimulation may be
irrelevant to our model of allo-BMT, we tested the prolif-
erative capacity of GITR    and GITR    T cells derived
from mice of a mixed background (C57BL/6   129/SvJ).
Our preliminary results indicate that there is no difference
in CD4 CD25  and CD8 CD25  T cell proliferation
upon allostimulation using third party stimulators (BALB/c;
unpublished data). However, these experiments were
performed with cells from GITR    and GITR    on a
mixed background and we cannot rule out that genetic dif-
ferences (other than the presence or absence of GITR)
could have affected the alloresponse. Therefore, definitive
experiments will have to be deferred until the GITR   
mice have been completely backcrossed ( N 10).
To test whether the in vitro effects of anti-GITR agonist
Ab (DTA-1) on alloreactive T cells were consistent in
vivo, sublethally irradiated BALB/c mice were treated with
DTA-1 or rat IgG control before adoptive transfer of
C57BL/6 CFSE-labeled CD4 CD25  or CD8 CD25  T
cells (Fig. 2 B). 3 d after T cell infusion, donor T cells were
recovered and analyzed by flow cytometry. The in vivo
proliferation profile of CFSE-labeled T cells allows the dis-
crimination of slow proliferating cells, described in some
models as homeostatic expansion, versus fast-dividing al-
loreactive T cells (24). GITR stimulation had no impact
on the proportion of slow dividing CD4 CD25  (12%
in controls vs. 13% in DTA-1–treated recipients) and
CD8 CD25  (24 vs. 27%) T cells. However, GITR stim-
ulation decreased the percentage of fast-dividing alloreac-
tive CD4 CD25  T cells (from 53 to 16%) and increased
the percentage of fast-dividing alloreactive CD8 CD25  T
cells (from 51 to 62%). There were more nondividing
CD4 CD25  T cells in the DTA-1–treated group (71% in
DTA-1–treated recipients vs. 35% in the controls), and
Figure 2. GITR stimulation induces paradoxical responses in CD4 
CD25  and CD8 CD25  T cells in vitro and in vivo. (A) An anti-GITR
agonist Ab (DTA-1; 10  g/ml) was added to MLRs of purified
CD4 CD25  and CD8 CD25  splenic T cells as effector cells (105) with
irradiated splenocytes as stimulators (2   105). (Wild-type stimulators)
C57BL/6 effectors and BALB/c stimulators. (GITR    and GITR   
stimulators) BALB/c effectors and GITR    or GITR    stimulators
(C57BL/6   129/SvJ).  Stim, without stimulators.  Stim, with stimu-
lators. *, P   0.001. (B) Proliferative profile of recovered CFSE-labeled
CD4 CD25  and CD8 CD25  T cells from sublethally irradiated hosts
treated with 10  g/ml DTA-1 or rat IgG control. These data are repre-
sentative of three independent experiments. (top left) Percentage of alloreac-
tive fast-proliferating donor T cells. (center) Percentage of slow proliferating
donor T cells. (top right) Nondividing donor T cells.Muriglan et al. 153
fewer nondividing CD8 CD25  T cells in the DTA-1–
treated group (11 vs. 25%) compared with the control Ab
groups. These results indicate that GITR stimulation in
vivo can inhibit alloreactive CD4 CD25  expansion while
it enhances alloreactive CD8 CD25  expansion.
Fas–FasL Mediate GITR Inhibition of CD4 CD25  T
Cell Expansion. To determine if the Fas–FasL pathway
was involved in GITR inhibition of CD4 CD25  expan-
sion, we studied the effect of GITR stimulation on cell
surface expression of Fas and FasL (Fig. 3 A). CD4 CD25 
and CD8 CD25  T cells allostimulated in the presence of
the agonistic anti-GITR Ab (DTA-1) did not increase Fas
expression nor was there a difference in FasL expression
(unpublished data), although FasL cell surface expression is
notoriously difficult to demonstrate by flow cytometric
analysis. To address this question in a different assay, we
studied the effect of DTA-1 on T cells from Fas-deficient
lpr mice (Fig. 3 B). Addition of DTA-1 to an MLR had no
effect on proliferation by lpr CD4 CD25  T cells, in con-
trast with the inhibitory effect on wild-type CD4 CD25 
T cells. Alloreactive proliferation of both wild-type and lpr
CD8 CD25  T cells was increased when DTA-1 was
added to the MLR. To demonstrate that GITR inhibition
of CD4 CD25  proliferation was due to FasL signaling,
we studied the effect of anti-FasL blocking Ab during allo-
stimulation (Fig. 3 C). As aforementioned, CD4 CD25 
T cell proliferation was impaired in the presence of DTA-1
while the addition of the FasL blocking Ab rescued
CD4 CD25  proliferation, although not completely. Be-
cause CD4 CD25  proliferation is not completely re-
stored after FasL blocking, other members of the TNFR
family could be implicated. Proliferation of purified CD4 
CD25  T cells from TNF    and TRAIL    mice allo-
stimulated in the presence of DTA-1 treatment remained
impaired (Fig. 3 D). We further tested the role of TNFR1
by using an anti-TNFR1 blocking Ab. Proliferation of pu-
rified CD4 CD25  T cells with TNFR1 and TNF block-
ing Ab in the presence of GITR stimulation still remained
impaired (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20040116/DC1). These results show that
GITR-mediated inhibition of CD4 CD25  T cell expan-
sion involves the Fas–FasL pathway and not the TNFR or
TRAIL pathways, although the involvement of other
members of the TNF family cannot be excluded.
Figure 3. Fas–FasL pathway is involved in inhibition of CD4 CD25 
proliferation. (A) Fas expression was determined on purified C57BL/6
CD4 CD25  and CD8 CD25  T cells 72 h after anti-GITR agonist Ab
(DTA-1) was added to MLRs with irradiated BALB/c stimulators.
(shaded histograms) Isotype control. (blue histograms) Rat IgG–treated
MLR. (red histograms) DTA-1–treated MLR. (B) DTA-1 was added
to MLRs with purified CD4 CD25  and CD8 CD25  from lpr
(B6.MRL-Faslpr) or wild-type (C57BL/6) mice as effectors and irradiated
BALB/c splenocytes as stimulators. These data are representative of three
experiments. *, P   0.001. (C) Purified C57BL/6 CD4 CD25  T cells
were stimulated with irradiated BALB/c splenocytes in the presence of rat
IgG control Ab, DTA-1 Ab, or DTA-1 plus MFL3, a FasL-blocking
Ab. These data are representative of two independent experiments. (D)
CD4 CD25  T cells were purified from wild-type C57BL/6, C57BL/6-
TNF   , and C57BL/6 TRAIL    mice and stimulated with irradiated
BALB/c splenocytes in the presence of rat IgG control Ab or DTA-1 Ab.
(unshaded bars) Rat IgG treatment. (shaded bars) DTA-1 treatment. Results
are presented as percent proliferation and are representative of two inde-
pendent experiments. *, P   0.007.
Figure 4. GITR stimulation induces early apoptosis of CD4 CD25 
alloreactive T cells after BMT. Lethally irradiated (900 cGy) BALB/c
recipients of C57BL/6 TCD-BM and C57BL/6 CD4 CD25  splenic T
cells were treated with DTA-1 or control Ab (1 mg i.p. on days  1 and
6). Spleens were harvested on days 3, 5, and 7, and stained for annexin V
( ) cells (n   3 per group, per time point). (A) Time course of the per-
centage of donor-derived annexin V ( ) cells is shown. *, P   0.0004.
(B) Absolute numbers of annexin V ( ) donor CD4  T cells at day 5.
*, P   0.05. (C) Representative FACS® analyses of annexin V ( ) donor
and host CD4  T cells at day 7.Paradoxical Effect of GITR Activation on Alloreactive T Cells 154
We measured the amount of IL-2 production of
CD4 CD25  T cells in the presence or absence of DTA-1
during allostimulation (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20040116/DC1). IL-2
was decreased in MLR supernatants of DTA-1–treated co-
cultures compared with control Ab–treated cocultures at
days 2 and 5 of coculture (day 2,  1.5 fold decrease and
day 5,  2.1-fold decrease). These decreased levels of IL-2
detected in our system may be a reflection of less viable
CD4 CD25  T cells.
These experiments indicate that GITR activation can
initiate Fas-mediated AICD of alloreactive CD4 CD25  T
cells, whereas GITR stimulation of CD8 CD25  T cell
proliferation is independent of Fas–FasL signaling.
In Vivo GITR Stimulation Increases Apoptosis of CD4 
CD25  Alloreactive T Cells. We wanted to address in
our GVHD model if GITR stimulation increased
CD4 CD25  apoptosis in vivo. We infused 3   106 puri-
fied CD4 CD25  T cells into lethally irradiated hosts
treated with DTA-1 or rat IgG control Ab and determined
apoptosis of donor T cells after 3, 5, and 7 d of allo-BMT
(Fig. 4 A). Donor CD4 CD25  T cells harvested from
spleens of DTA-1–treated recipients showed increased an-
nexin V staining when compared with donor T cells de-
rived from control recipients treated with rat IgG (Fig. 4, B
and C). We also studied the expression of activation mark-
ers at day 7 after BMT on CD4 CD25  T cells from the
DTA-1–treated group compared with the rat IgG–treated
group and detected no significant difference in the level of
CD25 and CD44 expression (unpublished data). These re-
sults indicate that DTA-1 treatment induces significantly
more apoptosis of donor alloreactive CD4 CD25  T cells
early in the course of GVHD.
GITR Stimulation Modulates GVHD. In the C57BL/
6→BALB/c strain combination, alloreactive CD4  T cells
are more potent as GVHD effectors (25), whereas graft-
versus-tumor activity is mostly dependent on alloreactive
CD8  T cells (26). We used this model to determine the ef-
fects of anti-GITR agonistic Ab (DTA-1) on alloreactive
CD4 CD25  and CD8 CD25  T cells during the devel-
opment of GVHD. Pilot experiments determined that
DTA-1 administration beginning at day  1 was optimal.
The dose and schedule were consistent with previous papers
in which anti-GITR antibodies have been used in vivo
(weekly administration of 1 mg i.p.; references 16, 27).
We hypothesized that DTA-1 administration to allo-
BMT recipients could ameliorate GVHD mediated by
CD4 CD25  T cells due to enhanced AICD of allo-
reactive T cells and aggravate GVHD mediated by
CD8 CD25  T cells due to their enhanced proliferation
by GITR stimulation. Indeed, we observed that DTA-1–
treated recipients of CD4 CD25  C57BL/6 donor T cells,
although not free of disease, had a significant delay and de-
crease in GVHD morbidity and mortality compared with
recipients treated with a control Ab (Fig. 5, left).
Although alloreactive CD4 CD25  cells are more po-
tent on a per cell basis in the C57BL/6→BALB/c model,
this strain combination has a class I and class II disparity,
and CD8 CD25  can induce GVHD. In other GVHD
models with full MHC disparity, CD8 -mediated GVHD
can always be demonstrated (28). DTA-1–treated re-
cipients of donor BM and donor CD8 CD25  T cells
had significantly increased GVHD morbidity and mortal-
ity (Fig. 5, right). Additional experiments in a MHC-
matched strain combination in which GVHD is primar-
ily dependent on alloreactive CD8  T cells (B10.BR→
CBA/J) demonstrated that DTA-1 administration to allo-
BMT recipients could aggravate GVHD (unpublished
data). However, these mice were infused with unfraction-
ated donor splenocytes; thus, increased mortality could
also be due to the inhibition of suppressor function via
GITR stimulation (15, 16) independent of its effect on
CD8  donor T cells.
To further assess GVHD, target organ histopathology
was studied (Fig. 6). Mice transplanted and infused with
donor CD4 CD25  donor T cells were killed at day 21
(Fig. 6 A). We lowered the dose of donor CD4 CD25  T
cells to 0.3   106 and delayed the time of organ harvest to
day 21 due to high mortality in the rat IgG control group
(Fig. 5). We observe significantly less GVHD target organ
damage in liver and intestines of DTA-1–treated recipients
compared with control recipients of CD4 CD25  T cells.
There was greater thymic cellularity in DTA-1–treated re-
cipients, which is consistent with less thymi damage. Also,
higher numbers of granulocytes were detected, consistent
with less GVHD-associated myelosuppression. Mice trans-
planted and infused with CD8 CD25  donor T cells were
killed, and organs were harvested at day 55, when differ-
ences in clinical scores were more pronounced (Fig. 6 B).
Consistent with our previous results, GITR stimulation of
Figure 5. GITR stimulation decreases GVHD mediated by
CD4 CD25  cells and increases GVHD mediated by CD8 CD25  T
cells. Lethally irradiated (900 cGy) BALB/c recipients of C57BL/6
TCD-BM and C57BL/6 CD4 CD25  or CD8 CD25  splenic T cells
were treated with DTA-1 Ab (1 mg i.p. on days  1, 6, and 13) or control
Ab. (top) Mean   SEM clinical GVHD scores. (bottom) Kaplan-Meier
survival curves. Data shown are combined from three experiments, n   15
per group. *, P   0.01.Muriglan et al. 155
donor CD8 CD25  donor T cells resulted in increased
target organ damage and myelosuppression.
Discussion
Previous experiments have indicated that in vitro stimula-
tion of GITR on immunoregulatory T cells inhibits their
suppressive effect and that in vivo GITR stimulation induced
development of autoimmunity presumably due to immuno-
regulatory T cell inhibition (15, 16). The effects of GITR
stimulation on CD4  and CD8  have not been fully ad-
dressed, especially in vivo. Here, we demonstrate that GITR
stimulation in vitro and in vivo has an important role in
the costimulation of alloreactive CD4 CD25  and CD8 
CD25  T cells independent of its effect on immunoregula-
tory T cells. Stimulation with a GITR-activating Ab in-
hibited CD4 CD25  proliferation and decreased GVHD,
whereas it enhanced alloreactive CD8 CD25  T cell prolif-
eration and increased GVHD. Our data indicate that GITR-
mediated inhibition of CD4 CD25  T cell expansion
involves the Fas–FasL pathway, suggesting that GITR
activation can initiate Fas-mediated AICD of alloreactive
CD4 CD25  T cells, whereas GITR stimulation of
CD8 CD25  T cell proliferation is independent of Fas–FasL
signaling. Our results are consistent with the notion that
GITR stimulation could lower the threshold for T cell acti-
vation inducing increased AICD in CD4 CD25 , but not in
CD8 CD25  T cells, where it induces proliferation. Thus,
GITR stimulation of alloreactive CD4 CD25  T cells in
vivo can provide a novel strategy to prevent or treat GVHD.
Other laboratories have described GITR signaling as co-
stimulatory for CD4 and CD8 (15, 17). Experiments using
polyclonal stimulation with low concentrations of plate-
bound or soluble anti-CD3 Ab (0.1–0.5  g/ml; references
15, 17, 18) demonstrate that anti-GITR increases prolifera-
tion, but in some experiments, this costimulation is lost at
higher concentrations of anti-CD3 Ab (1–3  g/ml; refer-
ences 15, 18). Our experiments addressing the role of
GITR stimulation using Ab stimulation showed no differ-
ence in the proliferation of CD4 CD25  cells stimulated
with 10  g/ml of soluble anti-CD3 and soluble anti-GITR
agonistic Ab (DTA-1). CD8 CD25  T cell proliferation
under the same conditions was slightly increased (unpub-
lished data). However, experiments addressing the effects
of GITR stimulation upon Ag-specific recognition, a more
representative model of allo-specific responses, show results
consistent with ours. Because GVHD is a Th1-mediated
complication of BMT (29, 30), experiments by Tone et al.
(11) with a Th1 clone derived from TCR transgenic mice
using a rGITRL for GITR stimulation are more relevant to
our model. When the Th1 clone is stimulated with a low
concentration of the cognate peptide (1 nM), rGITRL
proliferation is enhanced. In contrast, when the Th1 clone
is stimulated in the presence of rGITRL and higher peptide
concentrations (10–100 nM), proliferation is inhibited. The
same results were observed using naive T cells derived from
the same transgenic mice where the presence of GITR
stimulation at high peptide concentrations inhibited prolif-
eration (11).
Furthermore, Shimizu et al. (15) have shown that xeno-
stimulated CD4 CD25  T cells have decreased prolifera-
tion in the presence of anti-GITR agonistic Ab (DTA-1).
Murine CD4 CD25  T cells were stimulated with rat
APCs. The authors demonstrate that DTA-1 has no cross-
reactivity with rat APCs, indicating that any effect observed
by the addition of the agonist Ab will be a result of its di-
rect effect on the murine cells. When CD4 CD25  T cells
were xenostimulated in the presence of a control Ab, they
proliferate extensively, whereas addition of DTA-1 to the
same culture resulted in a marked decrease in proliferation.
Figure 6. GITR stimulation decreases GVHD-associated organ dam-
age mediated by CD4 CD25  T cells and increases GVHD-associated
organ damage mediated by CD8 CD25  T cells. Lethally irradiated (900
cGy) BALB/c recipients of C57BL/6 TCD-BM and C57BL/6
CD4 CD25  cells or CD8 CD25  splenic T cells were treated with
DTA-1 Ab or control Ab (1 mg i.p. on days  1, 6, and 13). Recipients
of CD4 CD25  T cells were killed, and organs were harvested on day 21
(A). Recipients of CD8 CD25  T cells were killed, and organs were
harvested on day 55 (B). (top) A semi-quantitative histopathological anal-
ysis for GVHD in liver, small bowel, and large bowel. (bottom left) The
absolute number of thymocytes. (bottom right) The absolute numbers of
splenic Mac-1  (M ), B cells, and granulocytes (Granul) were analyzed
by flow cytometry. Data shown are representative of one experiment,
n   9–10 per group. *, P   0.05.Paradoxical Effect of GITR Activation on Alloreactive T Cells 156
These experiments that analyze Ag-dependent T cell acti-
vation are very similar to our results, suggesting that during
allo- and xenostimulation the addition of GITR stimula-
tion may induce a potent costimulation, which can inhibit
proliferation at higher Ag concentration. Our experiments
indicate that this inhibitory effect on proliferation could be
due to AICD.
We believe that the overall effect of in vivo GITR stim-
ulation needs to be reconsidered because GITR stimulation
can have a differential and/or paradoxical effect on regula-
tory T cells, CD4  effector T cells, and CD8  effector T
cells. Our data in clinically relevant models for GVHD
suggest that in vivo GITR stimulation holds therapeutic
promise for the separation of CD8-mediated graft-versus-
tumor activity from CD4-mediated GVHD activity.
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